Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Molybdenum is an essential trace mineral and chemical element (atomic number 42, symbol Mo) required for human health. It acts as a cofactor in several key enzymes, including sulfite oxidase, xanthine oxidase, aldehyde oxidase, and mitochondrial amidoxime reducing component (mARC), which are involved in the metabolism of sulfur-containing amino acids, purines, pyrimidines, drugs, and toxins. Molybdenum deficiency is extremely rare but can be treated or prevented with supplementation. It is available as a dietary supplement and under the brand name Molypen for clinical use to address deficiency states[1][2][3][4]. Molybdenum is also used industrially in metallurgy and catalysis but its pharmaceutical use centers on nutritional supplementation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on molybdenum.